PNC Financial Services Group Inc. Increases Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

PNC Financial Services Group Inc. raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 14.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,613 shares of the medical equipment provider’s stock after purchasing an additional 1,202 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Lantheus were worth $596,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in LNTH. Tucker Asset Management LLC boosted its holdings in Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 282 shares in the last quarter. Principal Securities Inc. purchased a new stake in Lantheus in the 4th quarter valued at approximately $28,000. Covestor Ltd boosted its stake in shares of Lantheus by 62.7% during the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 203 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Lantheus by 36.6% during the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 156 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of Lantheus by 103.9% during the 4th quarter. First Horizon Advisors Inc. now owns 932 shares of the medical equipment provider’s stock worth $58,000 after acquiring an additional 475 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Mizuho boosted their price target on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Finally, Truist Financial boosted their price target on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $99.17.

Lantheus Price Performance

LNTH stock opened at $78.52 on Thursday. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $91.81. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84. The stock’s 50 day moving average price is $76.70 and its 200 day moving average price is $65.90. The firm has a market cap of $5.44 billion, a P/E ratio of 11.99 and a beta of 0.56.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.11. The company had revenue of $369.98 million during the quarter, compared to the consensus estimate of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now directly owns 62,898 shares in the company, valued at approximately $4,836,227.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Heinz Christoph Maeusli sold 18,373 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the completion of the sale, the director now directly owns 23,340 shares in the company, valued at approximately $1,848,294.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the sale, the chief accounting officer now owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The disclosure for this sale can be found here. In the last three months, insiders sold 32,269 shares of company stock worth $2,557,300. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.